Psychedelics
NEW YORK, March 10, 2021 /PRNewswire/ — DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence subject enrollment in a Phase 1/2a clinical trial of ibogaine […]
Mydecine Innovations Group Announces Plans to Spin Out of its U.S. Cannabis Assets
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), is pleased to announce that it has entered into an arrangement agreement dated March 10, 2020 (the “Arrangement Agreement”) with a newly-incorporated wholly-owned subsidiary, (“Spinco”). Under the Arrangement Agreement, Mydecine will transfer its [U.S.] Cannabis Assets (defined below) to SpinCo in accordance with a plan […]
Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA“), a biotechnology company that is a global leader in the emerging field of serotonergic psychedelic medicine, is pleased to announce that it has been approved for trading on the OTCQB Venture Market effective today, March 10, 2021. “The up-listing of our shares to […]
Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (“Mindset“), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that James Lanthier, CEO, and Joseph Araujo, CSO, will be presenting at the Stifel GMP Conference – Psychedelics: Addressing the Global Mental Health Crisis. Date: Thursday, March 11, 2021, 1:50 pm […]
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a business and pipeline update at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing the Global Mental Health Crisis as follows: Date: Thursday, March 11, 2021 Time: 1:00PM Eastern Time […]
Vancouver, B.C. – March 9, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FRA: 6UF) (“NeonMind”) is pleased to announce that on March 4, 2020 NeonMind engaged Philippe Martin as a drug development consultant. Mr. Martin has 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of immunology, oncology […]
NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) (“NeonMind“) is pleased to announce that on March 4, 2021 NeonMind engaged Philippe Martin as a drug development consultant. Mr. Martin has 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of immunology, oncology and neurology. NeonMind has engaged […]
Numinus To Expand State-Of-The-Art Psychedelics Research Laboratory
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021. A 7,500 square-foot expansion will be developed and housed in an existing Numinus-leased building […]
Core One Labs In Collaboration With KICT To Explore DMT Assisted Psychotherapy
Core One Labs Inc. (CSE: COOL), (OTC: CLABF),(Frankfurt: LD62, WKN: A2P8K3) is pleased to announce that in collaboration with Ketamine Infusions Centers ofTexas LLC (KICT) it is exploring a development program for N-dimethyltryptamine (DMT)assisted psychotherapy to address anxiety and depression. In December 2020 the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (UK) […]
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has received unconditional ethics approval from Veritas IRB for its integration protocol research study. This study will serve to inform the development of the company’s digital therapeutics platform, iSTRYM, […]
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland“) an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that the company’s Psychedelic VR experience named, Wisdom, has been accepted to […]
Pure Extracts and ShroomBloom Sign Psychedelic Mushroom Supply Letter of Intent
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that it has signed a Letter of Intent (LOI) with ShroomBloom Labs/Floja Bioscience Inc. (“ShroomBloom”) to enter into an agreement for the supply […]
Optimi Health Accelerates Psilocybin Clinical Trial Program with IMPACT
Optimi Health Corp. (CSE: OPTI) (“Optimi”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce a service agreement with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary. Optimi instituted a program in 2020 to identify […]
Why DELIC’s Latest Acquisition is a Complete Game-Changer
The Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) team has been at the forefront of the cannabis industry for over a decade. After building High Times into the giant it is today, they founded DELIC as an umbrella platform to target the nascent psychedelics industry through a combination of media properties, high-profile events, wellness clinics […]
Tryp Therapeutics Announces Application to List on OTCQB
Tryp Therapeutics (CSE: TRYP) (“Tryp” or the “Company”) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today that it has submitted its application for a listing to the OTCQB® Venture Market (“OTCQB”). The Financial Industry Regulatory Authority or FINRA has accepted the Company’s Form 211, […]
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company’s bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain trauma. Ibogaine is […]
Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research
Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada’s Controlled Drugs and Substances Act that enhance the Company’s ability to lead psychedelics research and support the global psychedelics sector. Numinus Wellness Inc. (CNW Group/Numinus Wellness […]
Psyence Group Launches its Functional Mushroom Brand, “GOODMIND” Makes Board Changes
Psyence Group Inc., a leading platform in naturally derived psychedelic therapy and the development and commercialization of related technologies and products (“Psyence”), is pleased to announce it has launched its functional mushroom brand, “GOODMIND”, through a South African-based special purpose vehicle (“SPV”) called Goodmind (Pty) Ltd (“Goodmind“). The SPV will be responsible for the production, […]
PsyBio Therapeutics Announces Retention of Market Maker
PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio”), a leader in the field of psychedelic research and drug development, announces that, subject to the receipt of approval by the TSX Venture Exchange (“TSXV”), it has retained Generation IACP Inc. (“Generation”) to provide market making services with the objective of maintaining a reasonable market and improving the liquidity of […]
MagicMed Industries Inc. (CSE: MGIC reserved)(“MagicMed” or the “Company“) announced today a collaboration among the Company, Dr. Suran Goonatilake and Dr. Eric Nyberg, renowned thought leaders in artificial intelligence (“AI”). Together the parties are building PsyAITM, a tool designed to provide comprehensive, pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies in an effort to modernize psychedelic […]
Cybin Inc. Announces Uplisting to OTCQB Venture Market
Cybin Inc. (NEO: CYBN) (OTCQB:CLXPF) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). Cybin will commence trading on the OTCQB with the market open on March 8, 2021, under the symbol “CLXPF”. The OTCQB, operated by OTC Markets […]
Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs
Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company’s data strategy design, study design and advise on regulatory relationships […]
Lobe Sciences Appoints NFL Alumni Association President, Bart Oates Esq. to Advisory Board
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board. Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field […]
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and clinical research. Ibogaine is a naturally occurring psychoactive compound extracted from the […]
Novamind Expands Leadership Team, Accelerating M&A
Novamind Inc., (CSE:NM)(OTC PINK:NVMDF) (“Novamind”), a leading mental health company specialized in psychedelic medicine, announces the appointment of Joseph Braganza to the role of Senior Vice President, Head of M&A. Mr. Braganza joins the senior leadership team with a mandate to lead Novamind’s M&A strategy, accelerating the Company’s expansion plans for its network of clinics, […]
Nova Mentis Launches Autism Microbiome Study in the United States
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)(“NOVA”), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: “Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes.” “NOVA’s mission is to discover more precise ways to diagnose […]
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland“) is pleased to announce the launch of its Virtual Telecounseling membership program on the Company’s iMicrodose Digital Care App in the Netherlands. The app currently in use by consumers, is accessible from phones, tablets or computers. The telecounseling membership program will […]
Atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
atai Life Sciences (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and joined by […]
NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMBDF) (FSE: 6UF) (“NeonMind“) is pleased to announce that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind’s preclinical trial. The provisional patent applications include data derived from NeonMind’s initial preclinical trial that began […]
Psyched Wellness Provides Update on Pre-Clinical Trial of its Muscimol Extract AME-1
Psyched Wellness Ltd. (CSE: PSYC,OTCQB: PSYCF, FRANKFURT:5U9) (“Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company has received the results from its Maximum Tolerated Dosage(MTD) study conducted by KGK Science, a licensed CRO in Canada. “I am pleased to share the […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
KetamineOne Capital is focused on consolidating medical clinics and becoming a North American leader in mental health treatments.
Hero Technologies Inc. is a cannabis company working toward a vertically-integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
